Tillie Doyle
The Pan-Cancer Atlas is a comprehensive initiative that revolutionizes our understanding of human tumors and cancer. By analyzing over 10,000 tumors across 33 prevalent cancer types, the Atlas provides invaluable insights into the molecular and genomic landscape of cancer. This large-scale collaboration, supported by the National Cancer Institute and the National Human Genome Research Institute, aims to identify molecular aberrations and their functional roles across tumor types. The Pan-Cancer initiative enables comparisons between different tumors, informing the development of effective therapies and advancing our knowledge of cancer biology. The Atlas is a dynamic resource, integrating new tumor types and data from various enterprises, and it plays a pivotal role in shaping future clinical research and improving patient outcomes.
| Characteristics | Values |
|---|---|
| Name | The Cancer Genome Atlas Pan-Cancer Analysis Project |
| Alternative names | Pan-Cancer Project, TCGA, Pan-Cancer Atlas |
| Description | A large-scale collaboration initiated and supported by the National Cancer Institute (NCI) and National Human Genome Research Institute (NHGRI) |
| Purpose | To identify and analyze aberrations in the tumour genome and phenotype that define cancer lineages and those that transcend them |
| Data | Analysis of over 11,000 tumours from 33 of the most prevalent forms of cancer |
| Outcome | A comprehensive, in-depth, and interconnected understanding of how, where, and why tumours arise in humans |
| Use | Essential resource for the development of new treatments in the pursuit of precision medicine |
Explore related products
What You'll Learn
The Pan-Cancer Project's goals and achievements
The Pan-Cancer Project is a collaborative initiative that aims to advance our understanding of cancer by assembling and analyzing large-scale data on various tumour types. The project is coordinated by the Cancer Genome Atlas (TCGA) Research Network and involves the integration of diverse datasets and analytical approaches. One of the primary goals of the project is to identify and analyze aberrations in the tumour genome and phenotype that define cancer lineages and those that transcend them. By comparing the first twelve tumour types profiled by TCGA, including glioblastoma multiform (GBM), breast carcinoma (BRCA), lung adenocarcinoma (LUAD), and ovarian carcinoma (OV), among others, the project strives to understand the molecular aberrations and their functional roles across tumour types. This knowledge will enable the extension of effective therapies from one cancer type to others with similar genomic profiles.
The Pan-Cancer Project has achieved significant milestones in its endeavours. It has successfully assembled and analyzed data from thousands of patients with primary tumours occurring in different sites of the body, covering a range of tumour types. Through its comprehensive analysis, the project has provided new insights into the molecular relationships across diverse human cancers. One notable achievement is the reclassification of human tumour types based on molecular similarity, indicating that the cell of origin influences but does not solely determine tumour classification. This has important implications for future clinical trial design and interpretation.
Additionally, the project has facilitated the identification of molecular aberrations at the DNA, RNA, protein, and epigenetic levels, providing a rich dataset for developing an integrated understanding of commonalities, differences, and emergent themes across tumour lineages. The Pan-Cancer initiative has also contributed to the discovery of novel oncogenic drivers, the establishment of molecular subtypes, and the identification of new biomarkers with clinical significance. For example, ductal breast cancer is now viewed as a collection of distinct diseases with specific subtypes.
Furthermore, the Pan-Cancer Project has laid the framework for future analytical processes, including the integration of new tumour types and data from other enterprises, such as pediatric cancers (TARGET) and adult cancers (ICGC). The project has also addressed critical questions in cancer biology that extend beyond a single-tumour perspective, as evidenced by the collection of Pan-Cancer manuscripts. The project's achievements have paved the way for the development of new treatments, with a focus on precision medicine, and have enhanced our understanding of the complex molecular landscape of cancer.
Retrieving Your EPF Number: PAN Card Connection
You may want to see also
Explore related products
$49 $59
$30.68 $32.99
![National Geographic Road Atlas 2026: Scenic Drives Edition [United States, Canada, Mexico]](https://m.media-amazon.com/images/I/814R4OsGtCL._AC_UL320_.jpg)
![National Geographic Road Atlas 2026: Adventure Edition [United States, Canada, Mexico]](https://m.media-amazon.com/images/I/81rRihqWqgL._AC_UL320_.jpg)
The Cancer Genome Atlas (TCGA) Research Network
Following the success of the pilot phase, TCGA expanded its efforts to characterise additional cancer types and provide a rich and large genomic dataset for further cancer research. Ultimately, the project molecularly characterised over 20,000 primary cancer and matched normal samples spanning 33 cancer types, including 10 rare cancers. This involved bringing together researchers from diverse disciplines and multiple institutions.
TCGA generated over 2.5 petabytes of data, including genomic, epigenomic, transcriptomic, and proteomic data, which remains publicly available for the research community to use. This data has already led to improvements in our ability to diagnose, treat, and prevent cancer. It has also changed our understanding of cancer and how research is conducted, and it will continue to serve as a valuable resource for researchers.
In 2018, the TCGA Research Network published the Pan-Cancer Atlas, a collection of 35 papers summarising the work accomplished by TCGA. This collection delves into overarching themes of cancer biology, including cell-of-origin patterns, oncogenic processes, and signalling pathways. The Pan-Cancer Atlas provides a panoramic view of the oncogenic processes contributing to human cancer and reveals how germline genetic variants and somatic mutations collaborate in cancer progression. It also identifies patterns of vulnerabilities that will aid in the development of personalised treatments and new combination therapies.
Removing Oil Pan from 98 Volvo S70: Step-by-Step Guide
You may want to see also
Explore related products
Tumour genome and phenotype analysis
The Pan-Cancer Atlas is a large-scale collaboration initiated and supported by the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI). It provides a comprehensive and in-depth understanding of how, where, and why tumours arise in humans by analysing over 11,000 tumours from 33 of the most prevalent forms of cancer. The atlas is divided into three main categories: cell-of-origin patterns, oncogenic processes, and signalling pathways.
The atlas reclassifies human tumour types based on molecular similarity, indicating that the cell of origin influences but does not solely determine tumour classification. This informs the design and interpretation of future clinical trials. Companion work reveals new insights into the subgroupings of cancers, including gynaecological and breast, gastrointestinal, squamous, and renal cancers, and identifies stem-cell-like features associated with oncogenic dedifferentiation.
The Pan-Cancer Atlas provides a panoramic view of the oncogenic processes contributing to human cancer. It reveals how germline genetic variants and somatic mutations collaborate in cancer progression and explores the impact of mutations on cell signalling and immune cell composition. This knowledge is essential for prioritising the development of new treatments and immunotherapies.
The atlas identifies hundreds of predisposing germline variants and analyses over 9,000 tumours across 33 cancer types to highlight the prevalence of clinically actionable cancer driver events. It also provides insights into tumour signalling pathways, revealing patterns of vulnerabilities that will aid in the development of personalised treatments and new combination therapies.
The Pan-Cancer project lays the framework for future analytical processes, including the integration of new tumour types and data from other enterprises. It aims to assemble coherent and consistent TCGA datasets across tumour types and platforms and analyse and interpret the data. The project contributes to our understanding of tumour genome and phenotype analysis by identifying and analysing aberrations that define cancer lineages and transcend particular lineages.
Cleaning Egg-Stained Cephalon Pans: Easy and Quick Solutions
You may want to see also
Explore related products
The future of cancer analysis
Cancer is one of the world's biggest killers, with around 10 million deaths per year due to the disease. However, the future of cancer analysis looks promising, with unprecedented breakthroughs in cancer science and medicine.
Innovative technologies such as AI and wearable devices will drive progress against a wide range of cancers, including those that have been especially difficult to treat. AI-based models are being trained to accurately and proportionally represent population groups affected by the type of cancer being studied. AI has the potential to revolutionize cancer research and patient care, with the ability to predict lung and breast cancer years before diagnosis. AI can also provide reliable trajectories of future cancer development, indicating which individuals may need to be screened more frequently.
In addition to AI, other technologies are also enabling a deeper understanding of cancer at a single-cell and single-molecule level. For example, advances in single-cell analysis of gene expression, chromatin accessibility, and methylation are helping to identify cancer cells that are able to resist treatment and eventually regrow the tumor. This understanding of the genetic makeup of cancer has led to the identification of mutations that contribute to cancer development, with promising advances in targeted therapeutics.
Furthermore, cancer vaccines are also on the horizon, with thousands of NHS cancer patients in England set to access trials of a new vaccine treatment. This vaccine is designed to prime the immune system to target cancer cells and reduce recurrence risk, with fewer side effects than conventional chemotherapy.
Overall, the future of cancer analysis looks promising, with innovative technologies and research advancements driving progress against this deadly disease.
Cast Iron Pan Cornbread: The Perfect Mix Amount for a Dozen Servings
You may want to see also
Explore related products
The Pan-Cancer Atlas papers
The Pan-Cancer Atlas is a large-scale collaboration initiated and supported by the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI). The Atlas provides a comprehensive and in-depth understanding of how, where, and why tumors arise in humans, by analyzing over 11,000 tumors from 33 of the most common cancer types. This analysis has resulted in the publication of 27 papers, which are divided into three main categories: cell-of-origin patterns, oncogenic processes, and signaling pathways.
The first category, cell-of-origin patterns, focuses on the molecular classification of tumors based on their cell of origin. This category includes companion work that provides new insights into the subgroupings of cancers, such as gynecologic and breast cancers, gastrointestinal cancers, and squamous cell cancers. The analysis reveals that the cell of origin influences but does not solely determine tumor classification, which has important implications for future clinical trial design and interpretation.
The second category, oncogenic processes, explores the complex impact of genome alterations on the signaling and multi-omic profiles of human cancers. This category includes papers that analyze the prevalence of clinically actionable cancer driver events and the collaboration between germline genetic variants and somatic mutations in cancer progression. By understanding how these variants and mutations influence tumor microenvironments and immune cell composition, researchers can prioritize the development of new treatments and immunotherapies.
The third category, signaling pathways, focuses on the analysis of tumor signaling pathways and the identification of patterns of vulnerabilities. This category includes papers that study pathways such as MYC, RAS, ubiquitin, DNA damage repair, and metabolism. By integrating mutation, copy number, and expression data, researchers can detect Ras-activating variants in tumors and sensitivity to MEK inhibitors in cell lines, leading to the development of personalized treatments and new combination therapies.
Overall, the Pan-Cancer Atlas papers provide a comprehensive overview of the molecular landscape of cancer, with the goal of improving patient outcomes by extending effective therapies across tumor types with similar genomic profiles.
Garlic Prawns in Hot Pot: A Sizzling Sensation
You may want to see also
Frequently asked questions
The Pan-Cancer Atlas is a product of The Cancer Genome Atlas (TCGA) consortium. It provides a comprehensive, in-depth, and interconnected understanding of how, where, and why tumors arise in humans.
The Pan-Cancer Atlas identifies molecular relationships across a large and diverse set of human cancers, suggesting future directions for exploring clinical actionability in cancer treatment.
The Pan-Cancer Project identifies and analyzes aberrations in the tumor genome and phenotype that define cancer lineages and those that transcend them.
The Pan-Cancer Analysis Project was launched by TCGA at a meeting held on October 26-27, 2012, in Santa Cruz, California. It aims to develop an integrated picture of commonalities, differences, and emergent themes across tumor lineages.
